Lamivudine/Zidovudine

拉米夫定/齐多夫定

Report date: 2022/12/07 17:53:03

Base Information

Drug NameLamivudine/Zidovudine
Drug Alias Name齐多拉米双夫定Lamivudine and Zidovudine齐多夫定/拉米夫定Lamivudine/AzidothymidineCombivir +[6] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionHuman immunodeficiency virus type 1 reverse transcriptase inhibitorsReverse transcriptase inhibitors
TargetsReverse transcriptaseHuman immunodeficiency virus type 1 reverse transcriptase
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsHIV Infections
Approved Indications in ChinaHIV Infections
Original Approved Country/TerritoryUnited States
Original Approved Date1997/09/26
Country/TerritoryUnited StatesPuerto RicoEU +[5] 
CombinationsYes LamivudineZidovudine
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesViiv Healthcare
China Registration ClassN/A

Develop Information

Active CompaniesViiv Healthcare BvGlaxo Wellcome Australia Pty LtdViiv Healthcare
Inactive CompaniesNational Institute Of Allergy And Infectious Diseases (Niaid)Viiv Healthcare Co
Active IndicationsHIV Infections
Inactive IndicationsN/A

Other Information

ATC CodeJ05AR01
Related LinksKEGG